HHS Adult and Adolescent Antiretroviral Treatment Guidelines Updated

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents announces the release of the updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.   Key additions and revisions to the guidelines include: Updated recommendation on integrase strand transfer inhibitor (INSTI) resistance testing in individuals failing an INSTI-based regimen Guidance on use of a newly available genotypic tropism assay to predict HIV-1 coreceptor usage Updated recommendations on initiation of antiretroviral therapy (ART) in treatment-naive individuals Updates to What to Start, including guidance on use of rilpivirine (RPV)-based regimens and elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COBI/TDF/FTC) in ART-naive individuals Strengthening of recommendation for initiation of ART in individuals with acute/recent (early) HIV infection from “should be considered optional (CIII)” to “should be offered (BII)” Updated recommendations on the use of efavirenz (EFV) during pregnancy and IV zidovudine (ZDV) during labor to mirror recent changes in the Perinatal Guidelines New information describing the use of ritonavir (RTV) and COBI as pharmacokinetic enhancers in the drug interaction section Updates to the drug interaction tables, including the addition of known and predicted interactions involving EVG/COBI and other drugs For a complete preview of key updates to the guidelines, please see...